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Susceptibility pattern of Streptococcus pneumoniae in
outpatients in Germany
During a 1992^97 German surveillance study, Reinert et al
[1] found no penicillin-resistant Streptococcus pneumonaie strains
among blood culture isolates (n 200).We report the suscept-
ibility pattern of recent S. pneumoniae strains (only one per
patient) isolated from outpatients seen in general practice or in
ourOutpatientDepartment.Themajorityof the S. pneumoniae
strains (n 89) were cultured from material sent to a labora-
tory serving general practitioners in the Frankfurt area
(EJKR) in 1998. Only eight strains (three of them in winter
1999) were cultured frompatients who consulted the Outpati-
ent Department of our Hospital. The sources of the strains
were: upper respiratory tract (63); lower respiratory tract (17);
blood/cerebrospinal £uid (6); ear (5); others (6). Minimum
inhibitory concentrations (MIC) were determined for penicil-
lin (PEN), erythromycin (ERY), doxycycline (DOXY), clin-
damycin (CLIN), levo£oxacin (LEV) and moxi£oxacin
(MOX) using the E test method. Three S. pneumoniae strains,
with a penicillin MIC of 0.5, 2.0 and 4.0mg/L, respectively,
provided by Dr Bryskier, France were used as quality control
strains.
The MIC distribution of the 97 strains tested is given in
Table1. The rate of resistance at break-points de¢ned in the
Alexander Study [2] to PEN is 4.1%, to ERY is 15.5%, and to
DOXY is 15.5%. As recommendations from an independent
source such as DIN (Deutsches Institut fuer Normung e.V.) are
still missing, we used the break-points suggested by several
German pharmaceutical companies: MOX,R1mg/L for sen-
sitivity, r4mg/L for resistance; LEV, R2mg/L for sensitiv-
ity, r8mg/L for resistance. At these admittedly high break-
points for the newer quinolones none of the strains was classi-
¢ed as resistant (Table 2).
Four out of 97 strains which we collected in 1998^99 were
resistant to penicillin.We believe this is the highest incidence
of penicillin-resistant pneumococci reported so far from Ger-
many. In the present study we found 15.5% (15/97) erythro-
Table 1 Number of strains inhibited at given concentrations (E test dilutions in mg/L)
Drug Name 0.006 0.008 0.012 0.016 0.023 0.032 0.047 0.064 0.094 0.125 0.19 0.25 0.38 0.5 0.75 1
PEN 1 1 43 27 10 1 2 3 3 1 1
ERY 1 10 13 43 14
DOXY 2 2 9 7 8 16 30 4 1
CLIN 2 1 1 3 10 23 28 13 2 1
MOX 1 17 39 37 3
LEV 1 7 16 29
Drug Name 1.5 2 3 4 6 8 12 16 24 32 64 128 r256
PEN 2 2
ERY 1 1 14
DOXY 1 1 1 3 4 3 3 2
CLIN 13
MOX
LEV 36 7 1
PEN, Penicillin G; ERY, erythromycin, DOXY, doxycyclin; CLIN, clindamycin; MOX, moxi¯oxacin; LEV, levo¯oxacin.
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mycin resistance, which is markedly higher than the 3%
(only six out of 200 strains collected between 1992 and 1996)
reported recently by Reinert et al [3] for Germany, and re£ects
the trend reported by Kresken et al [4] who observed an
increase in erythromycin resistance (break-point r1mg/L,
which is lower than the one used in the Alexander Project [2])
from 3.6% in 1992 to 11.3% in 1997. Frankfurt (if not Ger-
many) seems to have joined the c`lub of countries with penicil-
lin-resistant pneumococci'.
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Localized Mycobacterium avium complex infection in a
patient on HAART
The increases in CD4 T-lymphocytes count induced by anti-
retroviral therapy provide an anti-infective protection such
that primary prophylaxis against opportunistic infections can
be stopped. There is, however, concern that CD4 count aug-
mented by drug therapy may not include cells speci¢cally
active against some of the frequent opportunistic infections,
including atypical mycobacterial infections [1].
We report a case ofMycobacterium avium intracellulare occur-
ing in a 55-year-old retired bank manager who had been
unwell for about 9 months with repeated respiratory chest
infections and loss of weight. He was thought initially to have
an underlying neoplasm and had undergone extensive investi-
gations including a whole body CT (computed axial tomo-
graphic) scan at the referring hospital. He was divorced in 1978
and during the 1980s had multiple homosexual contacts. Dur-
ing the 2weeks prior to being referred he had become progres-
sively short of breath associated with a dry cough. Physical
examination was essentially normal apart from a temperature
of 37.5 C. His chest X-ray revealed bulky hilar lymphadeno-
pathy and there were patchy opacities of both the mid-zones.
Blood gas analysis revealed pO2 10.6 kPa (4.5^6.1) and pCO2
4.1kPa (12.0^14.0). Pulmonary function tests showed that the
TLCO was 6.77mmol/min/kPa (62% of expected) and kCO
was 1.18mmol/min/kPa/L (84% of expected). Although
induced sputums taken for indirect immuno£uorescent anti-
body stain against Pneumocystis carini were negative, a subse-
quent broncho-alveolar lavage examination was strongly
positive. Acid-fast bacilli were not demonstrated. He was
commenced on high dose cotrimoxazole (120mg/kg per day)
with prednisolone. He was counselled and consented to be
tested for HIV and this was shown to be positive (ELISA
Abbot (Abbot Laboratories, Chicago, USA); ELISAOrganon
(OrganonTeknika Ltd, Boxtel, the Netherlands) and INNO-
LIA Blot test (Ghent, Belgium)). The HIV load was noted to
Table 2 Breakpoints, R I S distribution, geom. mean and range of 97 pneumococcal strains
Drug name Breakpoints No. of strains %R %I %S MIC50 MIC90 Geom Mean Range
PEN S0.006; R2 97 4.1 9.3 86.6 0.023 0.125 0.03 0.00±2
ERY S0.0.5; R4 97 14.4 1.0 84.5 0.125 512 0.38 0.047±512
DOXY S0.2; R8 97 15.5 1.0 83.5 0.5 16 0.64 0.064±64
CLIN S0.0.5; R4 97 13.4 0 86.6 0.125 512 0.32 0.016±512
MOX S0.1; R4 97 0 0 100 0.19 0.25 0.20 0.094±0.38
LEV S0.2; R8 97 0 8 92 1 1.5 1.12 0.25±3
PEN, Penicillin G; ERY, erythromycin; DOXY, doxycyclin; CLIN, clindamycin; MOX, moxi¯oxacin; LEV, levo¯oxacin.
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